NCI to sponsor phase III trials of liquid shark cartilage angiogenesis inhibitor.
D000284:Administration, Oral; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002356:Cartilage; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D015337:Multicenter Studies as Topic; D009316:National Institutes of Health (U.S.); D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000473:pathology; D014020:Tissue Extracts / Q000008:administration & dosage / Q000627:therapeutic use*; D014481:United States
D000893:Anti-Inflammatory Agents; D014020:Tissue Extracts; C111481:shark cartilage extract